Form 8-K Apellis Pharmaceuticals, For: Jan 03
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
30,799$
10,99%
Echtzeit-Aktienkurs Apellis Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Apellis Pharmaceuticals Inc. Aktie
Apellis, Arvinas lower as Wells Fargo downgrades in 2023 biotech preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader…
Insiderhandel: Chief Executive Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 1.467.983$
Francois, Cedric - Vorstand - Tag der Transaktion: 2022-12-19...…
Insiderhandel: Aufsichtsrat verkauft Aktien von Apellis Pharmaceuticals im Wert von 65.438$
Machiels, Alec - Aufsichtsrat - Tag der Transaktion: 2022-12-15...…
Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe
Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the…
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and…
Insiderhandel: Chief Scientific Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 570.000$
Deschatelets, Pascal - Vorstand - Tag der Transaktion: 2022-12-08...…
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader…
Apellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings…
Insiderhandel: Chief Commercial Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 251.900$
Townsend, Adam J. - Vorstand - Tag der Transaktion: 2022-12-05...…
Premarket Movers: Elbit Systems, CME Group Cl A, Apellis Pharmaceuticals
Premarket Movers: Elbit Systems, CME Group Cl A, Apellis Pharmaceuticals...…
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader…
Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA
The FDA accepts Apellis (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular…
Thinking about trading options or stock in Ross Stores, Apellis Pharmaceuticals, Exxon Mobil, Meta Platforms, or Alibaba?
NEW YORK, Nov. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ROST, APLS, XOM, META, and BABA. Click…
Apellis shares gain 16% after FDA accepts new data for drug submission
Shares of Apellis Pharmaceuticals Inc. jumped 16.8% in premarket trading on Friday after the company said the Food and…
Apellis surges 17% as FDA accepts to review new data in filing for eye disorder drug
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Premarket Movers: Ross Stores, Apellis Pharmaceuticals, Palo Alto Networks
Premarket Movers: Ross Stores, Apellis Pharmaceuticals, Palo Alto Networks...…
Apellis Shares Jump Premarket as FDA Accepts Amendment >APLS
Apellis Shares Jump Premarket as FDA Accepts Amendment >APLS...…
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)
WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and…
Apellis, IVERIC bio cut to Hold at Jefferies; says Street overestimates GA market
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
5 Analysts Have This to Say About Apellis Pharmaceuticals
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter:
Latest Ratings for APLS
…
Insiderhandel: Chief Commercial Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 292.700$
Townsend, Adam J. - Vorstand - Tag der Transaktion: 2022-11-03...…
Form 10-Q Apellis Pharmaceuticals, For: Sep 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Apellis Pharmaceuticals Q3 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader…
Is a Surprise Coming for Apellis (APLS) This Earnings Season?
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....…
Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting
Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH) Robust…
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader…
Insiderhandel: Aufsichtsrat verkauft Aktien von Apellis Pharmaceuticals im Wert von 74.138$
Machiels, Alec - Aufsichtsrat - Tag der Transaktion: 2022-10-14...…
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader…
Insiderhandel: CHIEF MEDICAL OFFICER verkauft Aktien von Apellis Pharmaceuticals im Wert von 166.725$
Grossi, Federico - Vorstand - Tag der Transaktion: 2022-10-03...…
Insiderhandel: Chief Commercial Officer verkauft Aktien von Apellis Pharmaceuticals im Wert von 333.450$
Townsend, Adam J. - Vorstand - Tag der Transaktion: 2022-10-03...…